Secondary endpoints are ( @ ) tolerability and safety ; ( @ ) detection of the most sensitive neurocognitive instruments ; ( @ ) perceptions of Down syndrome adults and caregivers on whether to participate , and assessment experiences ; ( @ ) distributions of cognitive decline , adaptive behavior , general health/quality of life , service use , caregiver strain , and sample size implications ; ( @ ) whether A@/A@ is a cognitive decline biomarker .